HUE065194T2 - Kondrogenezis indukálására szolgáló vegyületek és készítmények - Google Patents

Kondrogenezis indukálására szolgáló vegyületek és készítmények

Info

Publication number
HUE065194T2
HUE065194T2 HUE21178695A HUE21178695A HUE065194T2 HU E065194 T2 HUE065194 T2 HU E065194T2 HU E21178695 A HUE21178695 A HU E21178695A HU E21178695 A HUE21178695 A HU E21178695A HU E065194 T2 HUE065194 T2 HU E065194T2
Authority
HU
Hungary
Prior art keywords
preparations
compounds
inducing chondrogenesis
chondrogenesis
inducing
Prior art date
Application number
HUE21178695A
Other languages
English (en)
Hungarian (hu)
Inventor
Ha-Soon Choi
Jiqing Jiang
James Paul Lajiness
Bao Nguyen
Hank Michael James Petrassi
Zhicheng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE065194T2 publication Critical patent/HUE065194T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999Small molecules not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE21178695A 2017-06-09 2018-06-07 Kondrogenezis indukálására szolgáló vegyületek és készítmények HUE065194T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
HUE065194T2 true HUE065194T2 (hu) 2024-05-28

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE21178695A HUE065194T2 (hu) 2017-06-09 2018-06-07 Kondrogenezis indukálására szolgáló vegyületek és készítmények

Country Status (38)

Country Link
US (3) US11091499B2 (enExample)
EP (3) EP4299123A3 (enExample)
JP (2) JP7229945B2 (enExample)
KR (1) KR102656524B1 (enExample)
CN (1) CN110719913B (enExample)
AR (1) AR113227A1 (enExample)
AU (1) AU2018279306C1 (enExample)
BR (1) BR112019025866A2 (enExample)
CA (1) CA3063985A1 (enExample)
CL (1) CL2019003564A1 (enExample)
CO (1) CO2019013706A2 (enExample)
CR (1) CR20190551A (enExample)
CU (1) CU24577B1 (enExample)
DK (1) DK3915994T3 (enExample)
DO (1) DOP2019000305A (enExample)
EA (1) EA201992858A1 (enExample)
EC (1) ECSP19086712A (enExample)
ES (1) ES2971319T3 (enExample)
FI (1) FI3915994T3 (enExample)
HR (1) HRP20240155T1 (enExample)
HU (1) HUE065194T2 (enExample)
IL (2) IL300755A (enExample)
JO (1) JOP20190282A1 (enExample)
LT (1) LT3915994T (enExample)
MA (2) MA50547A (enExample)
MX (1) MX389169B (enExample)
MY (1) MY198288A (enExample)
PE (1) PE20200403A1 (enExample)
PH (1) PH12019502764A1 (enExample)
PL (1) PL3915994T3 (enExample)
PT (1) PT3915994T (enExample)
RS (1) RS65161B1 (enExample)
SA (1) SA519410729B1 (enExample)
SI (1) SI3915994T1 (enExample)
TW (1) TWI782036B (enExample)
UY (1) UY37759A (enExample)
WO (1) WO2018225009A1 (enExample)
ZA (1) ZA201907358B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN113015735B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN113015736B (zh) 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950059B1 (en) * 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2008008884A2 (en) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2010232556A1 (en) 2009-04-02 2011-11-03 Allergan, Inc. Prostaglandin E receptor antagonists
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
CN101628951B (zh) 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ1デルタ(ck1デルタ)阻害剤
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
PE20161432A1 (es) * 2014-05-13 2017-01-08 Novartis Ag Compuestos y composiciones para inducir condrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) * 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
CR20190551A (es) 2020-01-28
AU2018279306C1 (en) 2021-01-14
WO2018225009A1 (en) 2018-12-13
CU24577B1 (es) 2022-02-04
JP2023062064A (ja) 2023-05-02
MX389169B (es) 2025-03-20
PT3915994T (pt) 2024-02-15
HRP20240155T1 (hr) 2024-04-12
JOP20190282A1 (ar) 2019-12-05
CA3063985A1 (en) 2018-12-13
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
TW201902900A (zh) 2019-01-16
JP2020522550A (ja) 2020-07-30
US11091499B2 (en) 2021-08-17
IL271154B2 (en) 2023-07-01
PL3915994T3 (pl) 2024-05-20
IL271154B1 (en) 2023-03-01
SI3915994T1 (sl) 2024-03-29
BR112019025866A2 (pt) 2020-07-14
AU2018279306B2 (en) 2020-07-09
CL2019003564A1 (es) 2020-06-19
EP4299123A3 (en) 2024-04-03
US20210079010A1 (en) 2021-03-18
EP3634967A1 (en) 2020-04-15
US20210347784A1 (en) 2021-11-11
KR20200013046A (ko) 2020-02-05
IL300755A (en) 2023-04-01
US12209096B2 (en) 2025-01-28
CN110719913A (zh) 2020-01-21
PE20200403A1 (es) 2020-02-26
RU2019144107A (ru) 2021-07-09
LT3915994T (lt) 2024-02-26
PH12019502764A1 (en) 2020-07-13
TWI782036B (zh) 2022-11-01
ZA201907358B (en) 2022-04-28
DK3915994T3 (da) 2024-02-19
KR102656524B1 (ko) 2024-04-12
SA519410729B1 (ar) 2022-07-03
CU20190098A7 (es) 2020-10-20
RS65161B1 (sr) 2024-02-29
EP4299123A2 (en) 2024-01-03
EP3915994B9 (en) 2024-02-28
US20230365580A1 (en) 2023-11-16
JP7229945B2 (ja) 2023-02-28
UY37759A (es) 2019-01-31
ES2971319T3 (es) 2024-06-04
FI3915994T3 (fi) 2024-02-14
MA57022B1 (fr) 2024-02-29
EP3915994A1 (en) 2021-12-01
AR113227A1 (es) 2020-02-19
NZ759434A (en) 2024-01-26
AU2018279306A1 (en) 2019-12-05
IL271154A (en) 2020-01-30
MY198288A (en) 2023-08-21
RU2019144107A3 (enExample) 2021-07-30
ECSP19086712A (es) 2019-12-27
MX2019014757A (es) 2020-02-12
US11753416B2 (en) 2023-09-12
MA50547A (fr) 2020-09-16
JP7432778B2 (ja) 2024-02-16
CN110719913B (zh) 2022-10-28
CO2019013706A2 (es) 2020-04-01
DOP2019000305A (es) 2019-01-15

Similar Documents

Publication Publication Date Title
IL282304A (en) Topical pharmaceutical compositions
IL281863A (en) Pharmaceutical compositions comprising meloxicam
IL272514A (en) Compositions and methods for modifying genomes
IL268684A (en) Compositions and methods for immunooncology
HUE061247T2 (hu) Termékek és készítmények
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
HUE056677T2 (hu) Anti-tim-3 ellenanyagok és készítmények
IL253719B (en) Pharmaceutical compositions for combination therapy
IL263846B (en) Formulation of a peptide vaccine
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
PT4070788T (pt) Formulações farmacêuticas
EP3645118C0 (en) SIMULATION-BASED DRUG TREATMENT PLANNING
IL258956A (en) Compositions and methods for tumor transduction
HUE053354T2 (hu) Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
MA43705A (fr) Formulation pharmaceutique
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
DK3723488T3 (da) Terapeutiske bakteriociner
HUE055762T2 (hu) Nyújtott hatású készítmények
PL3709970T3 (pl) Preparaty linezolidu
EP3383371A4 (en) PHARMACEUTICAL FORMULATION